Hospital Pharmacy presents this new feature to keep pharmacists abreast of new publications in the medical/pharmacy literature. Articles of interest will be abstracted monthly regarding a broad scope of topics. Suggestions or comments may be addressed to Joyce Generali, Director of Drug Information at Kansas University Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160 or jgeneral@kumc.edu.
Get full access to this article
View all access options for this article.
References
1.
BuusmanA., KragstrupJ., AndersenM.General practitioners choose within a narrow range of drugs when initiating new treatments: a cohort study of cardiovascular drug formularies. Eur J Clin Pharmacol.2005; 61: 651–656.
DemersC., McMurrayJ.J., SwedbergK.. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA.2005; 294: 1794–1798.
4.
MorettiR., TorreP., AntonelloR.M.. Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovscular events. A controlled, open label study. J Neurol.2005; 252: 1186–1193.
5.
SiegelJ.The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy.2005; 25: 78S–84S.
6.
DixonJ., FosterK., WyllieJ.. Guidelines and adenosine dosing in supraventricular tachycardia. Arch Dis Child.2005; 90: 1190–1191.
7.
MelloM.M., BrennanT.A.Legal concerns and the influenza vaccine shortage. JAMA.2005; 294: 1817–1820.
8.
MasoudiF.A., BaillieC.A., WangY.. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med.2005; 165: 2069–2076.
9.
MedfordA., MaskellN.Pleural effusion. Postgrad Med J.2005; 81: 702–710.
10.
PedersenT.R., FaergemanO., KasteleinJ.J.. High dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA.294(19): 2437–2445.
LinderJ.A., BatesD.W., LeeG.M.. Antibiotic treatment of children with sore throat. JAMA2005; 294(18): 2315–2322.
14.
MontoriV.M., DevereauxP.J., AdhikariN.K.. Randomized trials stopped early to benefit: a systematic review. JAMA.2005; 294(17): 2203–2209.
15.
KidonM.I., KangL.W., ChinC.W.. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal anti-inflammatory drugs among young, Asian atopic children. Pediatrics.2005; 116: 675–680.
WilkesS., EvansA., HendersonM.. Pragmatic, observational study of bupropion treatement for smoking cessation in general practice. PostgradMed J.2005; 81: 719–722.
18.
ScheneiderL.S., DagermanK.S., InselP.Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo controlled trials. JAMA.2005; 294(15): 1934–1943.
19.
GajdosP., TranchantC., ClairB.. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized, double blind clinical trial. Archives Neurol.2005; 62: 1689–1693.
20.
LambertiC., NainiA.B., LucchiniV.. Muscle coenzyme Q10 level in statin related myopathy. ArchNeurol.2005; 62: 1709–1712.
21.
ChowS.L., RooneyA.J., ClearyM.A.. The significance of elevated CSF lactate. Arch Dis Child.2005; 90: 1188–1189.
22.
GalieN., GhofraniH.A., TorbickiA.. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med.2005; 353: 2148–2157.
